Ademetionine 1,4-Butanedisulfonate

作者：唐立成 美工：何国红 罗真真 排版：马超 ▶ 引言 在今天，新药研发比拼的不只是技术，更是极限效率。 创新药竞争已进入白热化阶段。First-in-Class、Best-in-Class的卡位战，越来越依赖研发速度。然而，传统抗体早期研发仍深陷四大困局：周期长——分子筛选动辄3到6个月；人力依赖重——核心实验高度依赖科研人员的工时与熟练度；数据波动大——人工操作带来的批次差异，让重复验证成本居高不下；通量有限——受制于人力与场地边界，并行项目数量始终难以突破。 一个项目从靶点立项到完成候选抗体筛选，往往需要近半年时间。而半年，足以改变新药竞争格局。 有没有一种可能：让抗体筛选从“以月计”进入“以天计”？ 三优生物用一座“黑灯工场”给出了答案。 作为一家以“成为全球创新药研发的引领者”为愿景的生物医药高科技企业，三优生物依托智能超万亿分子库（AI-STAL）与三优智能新药加速器（SAI-DA）两大核心引擎，实现了国内领先的创新药全流程自动化、干湿闭环智能研发新范式——黑灯工场。 它将分子筛选周期从3-6个月压缩至14天，每年可承载超500个早期研发项目，目标推动新药整体研发周期缩短50%以上。 “黑灯工场”真正实现让机器解放人力，让数据定义精准，让速度成为新药孵化的核心引擎。 ▶ 一、解密「黑灯工场」：从"人追着实验跑"，到"实验自主运行" 什么是黑灯工场？用三个关键词足以讲清。 ★ 关键词一：全流程自动化 从分子构建、高通量筛选，到功能验证、数据分析、样品管理——黑灯工场真正实现了抗体药发现全流程的无人化运转。1200多台国际先进仪器设备在智能调度系统指挥下协同作业，覆盖临床前研发全流程。在这里，熄灯状态下全自主运转不是比喻，而是日常。 ★ 关键词二：干湿实验闭环 传统模式下，湿实验做完、人工整理数据、人工分析、再设计下一轮实验——循环每一步都需要人的介入，断裂而低效。 黑灯工场彻底重构了这一范式：湿实验平台产出的数据实时传输至AI算法系统（干实验），算法即时分析、自动决策、自动启动下一轮实验。数据驱动实验，实验反哺算法，形成“越跑越聪明”的智能闭环。三优智能新药加速器（SAI-DA）集成了数十种智能算法，让每一次筛选都成为下一轮优化的基石。 ★ 关键词三：黑灯运行 “黑灯”的真义，不是没有人，而是人不必在场。机械臂与算法在黑暗中精准穿梭，7×24小时全天候运转。人休息，机器不停机。科研人员从重复性劳动中彻底解放，回归靶点创新、方案设计与科学决策。彻底打破 8 小时工时与节假日的时间限制，让研发效率释放到最大，黑灯工场中，没有白天黑夜，只有永不停歇的研发脉搏。 ▶ 二、三大硬核标杆，重新定义行业效率 黑灯工场的价值，落在实打实的效率与产能突破上，具体来说，最终要用数据说话。 ＊标杆一：14天极速筛选，树起行业新标尺 传统模式：3-6个月。黑灯模式：14天。 这不是简单的速度提升，而是重新定义高活性抗体发现的“行业加速度”。智能超万亿分子库（AI-STAL）拥有十一万亿超大库容，超同行80多倍，优质先导分子数提升上百倍，筛选成功率接近100%，速度提升近10倍。叠加全流程自动化与干湿闭环智能调度，为新药研发抢出数月的关键窗口期。 14天，足以改变一条管线的竞争身位。 ＊标杆二：无人化通量与数据双革命 人工操作的误差，是实验数据波动的最大来源。不同人、不同天、不同批次——这些变量在黑灯工场中被彻底消除。 标准化机械操作让每一次实验都精准复刻，数据一致性、重现性极大提升，让大规模数据比对与AI模型训练拥有了“黄金标准”的输入。与此同时，设备全天候并行运转，单周期实验承载量较传统模式实现量级突破。 机器带来的是确定性，而确定性，是加速研发的底盘。 ＊标杆三：年承载500+项目，整体周期缩短50%以上 高通量的真正价值，不在于一个项目跑得快，而在于所有项目都能并行加速。 黑灯工场每年可支持超500个早期研发项目同步推进，实现工业化级别的并行开发。自动化贯穿序列优化、功能验证、可开发性评估全链条，推动从靶点到PCC（临床前候选化合物）的整体研发周期缩短50%以上。 这直接转化为药企的核心竞争力：更快的IND申报、更早的临床推进、更大的市场先机。 ▶ 三、不止于效率：四重价值重构 黑灯工场改变的，远不止研发速度。 ◐ 对科研人员：从“高级操作工”回归科学家 把重复性劳动交给机器，让科学家专注于他们最该做的事——靶点创新、方案设计、数据深度解读。用稳定、高质量的数据点燃创造力，而非消耗在移液和记录中。 ◑ 对合作伙伴：一站式降本、增效、控风险 更快交付、更稳数据、更高通量、更低试错成本。目前三优生物已与全球2000多家药企和生技公司建立合作，赋能1200多个新药研发项目，客户二次合作率达95%以上。黑灯工场将进一步降低早期研发门槛，为创新药企和Biotech提供确定性极高的早期研发底座。 ◐ 对生物医药行业：重塑抗体发现标准 推动行业从“人力驱动”向“智能驱动”转型，打造干湿闭环智能研发的示范样本。三优生物已累计申请170多项发明专利，获国家级高新技术企业、上海市专精特新等10余项资质认证，合作发表70多篇论文，含Science、Cell Research等顶刊。黑灯工场不是实验室里的概念，而是产业化落地的新基建。 ◑ 对临床与患者：让好药更快到来 研发周期的大幅压缩，推动创新抗体药更快从实验室走向临床。目前三优生物合作项目中已有10个完成IND申报，8个处于临床阶段，3个进入III期或确证性临床。黑灯工场的规模化产能，将让更多有价值的靶点以最快速度推进，更早满足未被满足的临床需求。 ▶ 四、从一座工场，到一个创新生态 一座黑灯工场，不可能一蹴而就。 它的背后，是三优生物多年来持续构建的创新研发体系。 以“智能超万亿分子库（AI-STAL）”为核心驱动，三优生物拥有自主知识产权的超大规模分子资源，库容量达到十一万亿级，在分子筛选速度、优质先导分子获取效率等方面均处于行业领先水平。 以“三优智能新药加速器（SAI-DA）”为依托，公司进一步将AI设计、干实验、湿实验、自动化平台和数字化研发体系深度融合，打造覆盖创新药研发全流程的智能研发平台。 黑灯工场背后，是三优生物的长期积累。对于三优生物而言，黑灯工场从来不是终点。 黑灯工场是公司打造全球顶尖原创新药创新工场的重要组成，也是三优生物"五五战略"目标的重要实践。 未来，三优生物将持续融合自动化、AI、高通量平台与数据智能，推动从“自动化实验”走向“智能研发”，不断完善智能研发体系。 三优生物始终认为，真正推动创新药发展的，不只是更先进的设备，而是更高效的协同。 因此，公司希望以智能研发平台为纽带，把科研机构、Biotech、药企以及全球合作伙伴连接起来，共筑创新药网络生态圈，让创新资源更加高效流动，让优秀项目更快走向临床。 正如三优生物一直坚持的使命： 让天下没有难做的创新药。 SAI-DA 1.0｜From 180 Days to 14 Days: How Sanyou Bio's "Lights-Out Factory" Is Redefining the Speed of Innovative Drug Discovery ▶ Introduction Today, success in innovative drug discovery is determined not only by technological excellence, but also by the ability to move faster than ever before. As the race for First-in-Class and Best-in-Class therapies intensifies, development speed has become one of the most critical competitive advantages. Yet early-stage antibody discovery continues to face four fundamental bottlenecks: Lengthy development cycles–Candidate screening typically requires three to six months. Heavy reliance on manual labor–Critical experimental workflows depend extensively on scientists' time and technical expertise. High data variability–Manual operations introduce batch-to-batch variation, increasing the cost of experimental reproducibility. Limited throughput–Laboratory capacity remains constrained by personnel and physical infrastructure, restricting the number of parallel programs. From target nomination to lead antibody identification, a single discovery program often takes nearly six months–more than enough time to reshape the competitive landscape of an emerging therapeutic area. But what if antibody discovery could be measured in days instead of months? At Sanyou Bio, the answer lies in a fully intelligent "Lights-Out Factory." Guided by its vision of becoming a global leader in innovative drug discovery, Sanyou Bio has established China's leading intelligent drug discovery paradigm by integrating two proprietary technology engines—its AI-Super Trillion Antibody Library (AI-STAL) and the Sanyou AI-Drug Accelerator (SAI-DA)—into a fully automated, AI-driven "dry-lab + wet-lab" closed-loop R&D platform. The result is transformative: Antibody screening time reduced from 3–6 months to just 14 days; Capacity to support more than 500 early-stage discovery programs annually; A long-term goal of shortening the overall innovative drug development timeline by more than 50%; The Lights-Out Factory is more than an automation platform—it represents a new paradigm where machines liberate scientists, data drives precision, and speed becomes the engine of innovation. ▶ I. Inside the Lights-Out Factory: From "Scientists Running Experiments" to "Experiments Running Themselves" What exactly is a Lights-Out Factory? Three key concepts explain it best. ★ 1. End-to-End Automation From molecular construction and high-throughput screening to functional characterization, data analysis and sample management, the Lights-Out Factory enables a fully automated antibody discovery workflow. More than 1,200 internationally advanced instruments operate in coordination under an intelligent scheduling system, covering virtually every stage of preclinical antibody discovery. Here, lights-out operation is not a metaphor—it is the everyday reality. ★ 2. An Intelligent Closed Loop Between Dry Lab and Wet Lab In traditional drug discovery, the workflow is fragmented: Wet-lab experiments are completed first, followed by manual data processing, manual analysis, and then the design of the next round of experiments. Every iteration requires extensive human intervention, making the process slow and inefficient. The Lights-Out Factory completely redefines this model. Experimental data generated by the wet-lab platform are transmitted in real time to AI-powered computational systems (the dry lab), where intelligent algorithms immediately analyze results, make decisions, and automatically initiate the next experimental cycle. Data continuously drives experimentation, while experimental outcomes continuously improve the AI models, creating a self-reinforcing learning loop that becomes smarter with every iteration. At the heart of this ecosystem is the Sanyou AI-Drug Accelerator (SAI-DA), which integrates dozens of AI algorithms, enabling every screening campaign to become the foundation for the next round of optimization. ★ 3. True "Lights-Out" Operation The essence of a Lights-Out Factory is not the absence of people—it's the absence of the need for people to be physically present. Powered by robotic systems and intelligent algorithms, the facility operates 24 hours a day, 7 days a week, even in complete darkness. Scientists rest. The factory doesn't. By eliminating repetitive manual work, researchers are free to focus on what truly creates value: target innovation, experimental strategy and scientific decision-making. Freed from the constraints of working hours, weekends and holidays, R&D productivity reaches an entirely new level. Inside the Lights-Out Factory, there is no distinction between day and night—only the uninterrupted pulse of innovation. ▶ II. Three Performance Benchmarks That Redefine Industry Efficiency The true value of the Lights-Out Factory lies not in the concept itself, but in the measurable breakthroughs it delivers in productivity, throughput, and development speed. Ultimately, performance speaks through data. ＊Benchmark 1: 14-Day Antibody Screening—Setting a New Industry Standard Traditional approach: 3–6 months Lights-Out Factory: 14 days This is far more than an incremental improvement—it represents a fundamental redefinition of the industry's speed for high-activity antibody discovery. Powered by the AI-Super Trillion Antibody Library (AI-STAL), which has 11-trillion ultra-large library capacity with proprietary IP—more than 80 times larger than conventional libraries—Sanyou Bio dramatically expands the probability of identifying high-quality lead candidates. The platform delivers over a hundred-fold increase in premium lead molecules, achieves a screening success rate approaching 100%, and improves discovery efficiency by nearly tenfold. When combined with end-to-end automation and an AI-driven dry-lab/wet-lab closed-loop workflow, the platform compresses months of discovery work into just two weeks—creating invaluable time advantages for innovative drug development. Fourteen days can redefine the competitive position of an entire drug pipeline. ＊Benchmark 2: A Dual Revolution in Throughput and Data Quality Experimental variability has long been one of the greatest obstacles to reliable drug discovery. Different operators. Different days. Different experimental batches. Each introduces variability that compromises data consistency and increases the need for repeated validation. The Lights-Out Factory fundamentally changes this. Standardized robotic operations ensure every experiment is performed with exceptional precision and reproducibility, dramatically improving data consistency across projects and generating high-quality datasets ideally suited for large-scale comparative analysis and AI model training. At the same time, automated instruments operate continuously around the clock, enabling large numbers of experiments to run simultaneously. Compared with conventional laboratory operations, experimental throughput has increased by orders of magnitude. Machines bring consistency. Consistency builds confidence. And confidence is the foundation for faster, smarter drug discovery. ＊Benchmark 3: Supporting More Than 500 Discovery Programs Every Year While Reducing Overall Development Timelines by Over 50% The real value of high-throughput technology is not simply accelerating a single project—it is enabling hundreds of projects to advance simultaneously. The Lights-Out Factory can support more than 500 early-stage drug discovery programs annually, delivering industrial-scale parallel development. Automation spans the entire discovery workflow—from sequence optimization and functional validation to developability assessment—accelerating every step from target identification to Preclinical Candidate (PCC) selection. As a result, the overall timeline from target discovery to PCC can be reduced by more than 50%. For pharmaceutical and biotechnology companies, these efficiencies translate directly into competitive advantages: Faster IND submissions; Earlier clinical development; Greater first-mover opportunities in the market. In today's increasingly competitive landscape, speed is no longer merely an operational advantage—it has become a strategic asset. ▶ III. Beyond Speed: Four Dimensions of Value Creation  The Lights-Out Factory transforms far more than development timelines. It is redefining how scientists work, how pharmaceutical companies innovate, how the industry evolves, and ultimately how patients gain access to life-changing therapies. ◐ For Scientists: From Skilled Operators Back to Scientific Innovators Automation assumes responsibility for repetitive laboratory tasks, allowing scientists to focus on what matters most: Identifying novel therapeutic targets Designing innovative experimental strategies Extracting meaningful biological insights from complex datasets Rather than spending valuable time pipetting samples or recording experimental results, researchers can devote their expertise to scientific innovation. Stable, high-quality data fuels creativity instead of consuming it. ◑ For Partners: One Platform to Reduce Cost, Increase Efficiency and Lower Risk The Lights-Out Factory offers pharmaceutical companies and biotech innovators a compelling combination of: Faster project delivery More reliable data Greater experimental throughput Lower trial-and-error costs  To date, Sanyou Bio has established partnerships with more than 2,000 pharmaceutical and biotechnology companies worldwide, supporting over 1,200 innovative drug discovery programs while maintaining a customer repeat collaboration rate exceeding 95%. By further lowering the barriers to early-stage discovery, the Lights-Out Factory provides partners with a highly predictable and scalable foundation for innovative drug development. ◐ For the Biopharmaceutical Industry: Redefining the Standard for Antibody Discovery The Lights-Out Factory represents a shift from labor-intensive discovery to AI-driven innovation, establishing a new benchmark for intelligent drug discovery through seamless integration of dry-lab and wet-lab technologies. Sanyou Bio has: Filed more than 170 invention patentsReceived over 10 national and international certifications, including National High-Tech Enterprise and Shanghai "Specialized, Refined, Distinctive and Innovative" Enterprise recognition Co-authored more than 70 scientific publications, including papers published in leading journals such as Science and Cell Research The Lights-Out Factory is not simply a laboratory concept—it is next-generation research infrastructure already operating at industrial scale. ◑ For Clinicians and Patients: Bringing Better Medicines to Patients Faster Every reduction in development time means patients may gain earlier access to innovative therapies. By significantly shortening discovery timelines, the Lights-Out Factory accelerates the transition of innovative antibody therapeutics from laboratory research to clinical development. Among Sanyou Bio's collaborative programs: 10 projects have completed IND submissions8 candidates are currently in clinical development3 programs have advanced to Phase III or confirmatory clinical studies With its industrial-scale discovery capacity, the Lights-Out Factory enables more promising therapeutic targets to progress rapidly toward the clinic, helping address unmet medical needs sooner and delivering greater hope to patients worldwide. ▶ IV. From a Single Factory to a Global Innovation Ecosystem A Lights-Out Factory is not built overnight. Behind it lies years of technological innovation, strategic investment, and continuous platform development by Sanyou Bio. At the core of this intelligent R&D ecosystem is the AI-Super Trillion Antibody Library (AI-STAL)—Sanyou Bio's proprietary ultra-large antibody library platform. With a capacity of 11 trillion antibody molecules, AI-STAL ranks among the industry's largest and most advanced antibody libraries, providing significant advantages in screening speed, hit identification, and the discovery of high-quality lead antibodies. Building upon this foundation, the Sanyou AI-Drug Accelerator (SAI-DA) further integrates artificial intelligence, computational (dry-lab) research, wet-lab experimentation, laboratory automation, and digital R&D infrastructure into a unified intelligent drug discovery platform that spans the entire innovation process. The Lights-Out Factory is therefore not an isolated achievement—it is the culmination of Sanyou Bio's long-term commitment to intelligent drug discovery. For Sanyou Bio, however, the Lights-Out Factory is not the destination. It is a critical component of the company's vision to build a world-leading innovation engine for original drug discovery, as well as a key milestone in executing its long-term "5×5 Strategy." Looking to the future, Sanyou Bio will continue integrating automation, artificial intelligence, high-throughput technologies, and data intelligence to drive the evolution of drug discovery from automated experimentation to fully intelligent R&D. The company remains committed to continuously strengthening its intelligent discovery ecosystem, enabling faster scientific decision-making, more efficient innovation, and greater predictability throughout early-stage drug development. Yet Sanyou Bio believes that truly accelerating innovative drug discovery requires more than advanced technologies alone. It requires collaboration. Rather than viewing its intelligent R&D platform solely as an internal capability, Sanyou Bio envisions it as a bridge connecting academic institutions, biotechnology companies, pharmaceutical enterprises, and global innovation partners. By fostering a more connected innovation ecosystem, the company aims to promote the efficient flow of scientific resources, accelerate the translation of promising discoveries into clinical development, and ultimately bring innovative medicines to patients faster. As Sanyou Bio has always believed: To Make It Easy To Develop New Drugs Worldwide. 推荐阅读 AI驱动蛋白质从头设计，加速创新药物发现 兔单抗分子产生系统解决方案 SAI-DA 1.0 | 智优人源化加速器 SAI-DA 1.0 | GEOTA平台 三优CPO为抗衰老生物药研发全程护航 AI-STAL 2.0 | 智能化多肽亲和力成熟解决方案 AI-STAL 2.0 | 全程智能多肽分子产生系统解决方案 Clicklinks | 新药圈你好，我是原创新药创新工场 SAI-DA 1.0 | 创新药你好，我叫智能新药加速器 AI-STAL 2.0 | 做药人你好，我是AI-STAL Click & Go | 结直肠癌的差异化靶点 创新前沿 | OpenClaw化身生物医药智能工匠 Clicklinks | 三优AI-STAL 2.0-14天先导分子发现 浙江大学上海校友会莅临三优生物考察交流 Clicklinks | oneClick+ 人源化应用程序发布 三优大事记 | “荣膺上海市企业技术中心” 关于三优生物 三优生物是一家以“让天下没有难做的创新药”为使命，致力于透彻解决创新药源头创新问题的生物医药高科技企业。 公司以智能超万亿分子库（AI-STAL）为核心驱动，以智能新药加速器（SAI-DA）为依托，致力于一站式透彻解决创新药各类分子产生和新药研发问题。 公司致力于打造全球顶尖的原创新药创新工场，协同各方共同加速全球创新药的研发进程。 公司总部位于中国上海，在亚洲、北美洲、欧洲等多地建立了业务中心，形成了全球化的业务网络，现有投产及布局的研发及GMP场地20000多平方米。 公司已与全球2000多家药企、生技公司等建立了良好的合作关系，已赋能1200多个新药研发项目；已完成50多个合作研发项目，其中10多个协同研发项目已推至IND及临床研发阶段。 公司已申请170多项发明专利，其中30多项发明专利已获得授权，并获得了国家级高新技术企业、上海市专精特新、ISO9001、ISO27001等10余项资质及体系认证。